Fluarix Exhibited Immunogenicity Children

FLUARIX QUADRIVALENT was studied in a randomized, double-blind, active-controlled, non-inferiority, immunogenicity and safety trial. Subjects aged 3 through 17 years received 1 or 2 doses of FLUARIX QUADRIVALENT (n=791) or 1 of 2 formulations of a comparator trivalent influenza vaccine (TIV) (FLUARIX TIV-1, n=819 or TIV-2, n=801), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Immune responses were evaluated in sera obtained 28 days following 1 or 2 doses of FLUARIX QUADRIVALENT or the comparators (according to protocol cohort).¹